Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Centre Oscar Lambret
Endeavor Biomedicines, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Novartis
Duke University
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Baylor College of Medicine
DNAtrix, Inc.
RTOG Foundation, Inc.
Duke University
University of California, Davis
Northwestern University
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Medical College of Wisconsin
European Organisation for Research and Treatment of Cancer - EORTC
Duke University
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Francisco
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Center for Neurosciences, Tucson
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Duke University
National Institutes of Health Clinical Center (CC)
Duke University
GE Healthcare
Duke University